These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 25998699)

  • 21. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort.
    Schoonenboom NS; Reesink FE; Verwey NA; Kester MI; Teunissen CE; van de Ven PM; Pijnenburg YA; Blankenstein MA; Rozemuller AJ; Scheltens P; van der Flier WM
    Neurology; 2012 Jan; 78(1):47-54. PubMed ID: 22170879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biological markers of Alzheimer's disease.
    de Souza LC; Sarazin M; Teixeira-Júnior AL; Caramelli P; Santos AE; Dubois B
    Arq Neuropsiquiatr; 2014 Mar; 72(3):227-31. PubMed ID: 24676441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Biomarkers in spinal fluid of patients with dementia].
    Skogseth RE; Fladby T; Mulugeta E; Aarsland D
    Tidsskr Nor Laegeforen; 2011 Nov; 131(22):2235-8. PubMed ID: 22085948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overlap between frontotemporal dementia and Alzheimer's disease: cerebrospinal fluid pattern and neuroimaging study.
    Padovani A; Premi E; Pilotto A; Gazzina S; Cosseddu M; Archetti S; Cancelli V; Paghera B; Borroni B
    J Alzheimers Dis; 2013; 36(1):49-55. PubMed ID: 23568100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neprilysin-like activity correlates with CSF-Tau and phospho-tau in patients with Alzheimer's disease.
    Sorensen KC; Simonsen AH; Holmetoft UB; Hasselbalch SG; Heegaard NH
    J Alzheimers Dis; 2013; 37(2):379-87. PubMed ID: 23948879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CSF neurofilament light concentration is increased in presymptomatic
    Rostgaard N; Roos P; Portelius E; Blennow K; Zetterberg H; Simonsen AH; Nielsen JE
    Neurology; 2018 Jan; 90(2):e157-e163. PubMed ID: 29237796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease.
    Lista S; Garaci FG; Ewers M; Teipel S; Zetterberg H; Blennow K; Hampel H
    Alzheimers Dement; 2014 May; 10(3):381-92. PubMed ID: 23850330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of CSF biomarkers in the diagnostic work-up of mixed vascular-degenerative dementia.
    Engelborghs S; Le Bastard N
    J Neurol Sci; 2012 Nov; 322(1-2):197-9. PubMed ID: 22947896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia.
    Landqvist Waldö M; Frizell Santillo A; Passant U; Zetterberg H; Rosengren L; Nilsson C; Englund E
    BMC Neurol; 2013 May; 13():54. PubMed ID: 23718879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity.
    Hampel H; Mitchell A; Blennow K; Frank RA; Brettschneider S; Weller L; Möller HJ
    J Neural Transm (Vienna); 2004 Mar; 111(3):247-72. PubMed ID: 14991453
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebrospinal fluid levels of a 20-22 kDa NH2 fragment of human tau provide a novel neuronal injury biomarker in Alzheimer's disease and other dementias.
    Amadoro G; Corsetti V; Sancesario GM; Lubrano A; Melchiorri G; Bernardini S; Calissano P; Sancesario G
    J Alzheimers Dis; 2014; 42(1):211-26. PubMed ID: 24851856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebrospinal fluid biomarkers in Progranulin mutations carriers.
    Carecchio M; Fenoglio C; Cortini F; Comi C; Benussi L; Ghidoni R; Borroni B; De Riz M; Serpente M; Cantoni C; Franceschi M; Albertini V; Monaco F; Rainero I; Binetti G; Padovani A; Bresolin N; Scarpini E; Galimberti D
    J Alzheimers Dis; 2011; 27(4):781-90. PubMed ID: 21891865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Definite behavioral variant of frontotemporal dementia with C9ORF72 expansions despite positive Alzheimer's disease cerebrospinal fluid biomarkers.
    Wallon D; Rovelet-Lecrux A; Deramecourt V; Pariente J; Auriacombe S; Le Ber I; Schraen S; Pasquier F; Campion D; Hannequin D
    J Alzheimers Dis; 2012; 32(1):19-22. PubMed ID: 22766732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer's disease.
    Baldacci F; Toschi N; Lista S; Zetterberg H; Blennow K; Kilimann I; Teipel S; Cavedo E; Dos Santos AM; Epelbaum S; Lamari F; Dubois B; Floris R; Garaci F; Bonuccelli U; Hampel H
    Alzheimers Dement; 2017 Sep; 13(9):993-1003. PubMed ID: 28263742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease.
    Grossman M; Farmer J; Leight S; Work M; Moore P; Van Deerlin V; Pratico D; Clark CM; Coslett HB; Chatterjee A; Gee J; Trojanowski JQ; Lee VM
    Ann Neurol; 2005 May; 57(5):721-9. PubMed ID: 15852395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias.
    Antonell A; Tort-Merino A; Ríos J; Balasa M; Borrego-Écija S; Auge JM; Muñoz-García C; Bosch B; Falgàs N; Rami L; Ramos-Campoy O; Blennow K; Zetterberg H; Molinuevo JL; Lladó A; Sánchez-Valle R
    Alzheimers Dement; 2020 Feb; 16(2):262-272. PubMed ID: 31668967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebrospinal Fluid NrCAM is not a Suitable Biomarker to Discriminate between Dementia Disorders--A Pilot Study.
    Müller M; Claassen JA; Kuiperij HB; Verbeek MM
    J Alzheimers Dis; 2015; 46(3):605-9. PubMed ID: 25812850
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How many biomarkers to discriminate neurodegenerative dementia?
    Sancesario GM; Bernardini S
    Crit Rev Clin Lab Sci; 2015; 52(6):314-26. PubMed ID: 26292074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer's, but not in frontotemporal dementia.
    Bibl M; Gallus M; Welge V; Esselmann H; Wolf S; Rüther E; Wiltfang J
    J Neural Transm (Vienna); 2012 Jul; 119(7):805-13. PubMed ID: 22527776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Apraxia screening predicts Alzheimer pathology in frontotemporal dementia.
    Pawlowski M; Joksch V; Wiendl H; Meuth SG; Duning T; Johnen A
    J Neurol Neurosurg Psychiatry; 2019 May; 90(5):562-569. PubMed ID: 30305323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.